Research programme: anti-infectives - Cidara Therapeutics

Drug Profile

Research programme: anti-infectives - Cidara Therapeutics

Alternative Names: Antibody-drug conjugates - Cidara; C 001; C 016; CD 201

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics
  • Class Antibacterials; Antifungals; Antivirals; Echinocandins; Immunoconjugates; Immunotherapies; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Aspergillosis; Gram-negative infections; Viral infections

Most Recent Events

  • 22 Apr 2017 Antimicrobial data from a preclinical study in Gram-negative infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 28 Feb 2017 Cidara Therapeutics has patents pending for CD 201 and the CloudbreakTM immunotherapy platform
  • 21 Sep 2016 Cidara Therapeutics intends to file an IND application with the US FDA in USA for Gram-negative bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top